Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

necitumumab

Known as: Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide 
A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
SQUIRE was a phase III study of gemcitabine and cisplatin with or without necitumumab in patients with metastatic squamous NSCLC… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Highly Cited
2015
Highly Cited
2015
BACKGROUND Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to… Expand
  • table 1
  • figure 2
  • table 3
Highly Cited
2015
Highly Cited
2015
BACKGROUND Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
Highly Cited
2015
Highly Cited
2015
UNLABELLED Deregulated expression of MYC is a driver of colorectal carcinogenesis, suggesting that inhibiting MYC may have… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Review
2014
Review
2014
  • R. Cohen
  • Cancer treatment reviews
  • 2014
  • Corpus ID: 12213019
Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic of head and neck squamous cell… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2014
Review
2014
Historically, the treatment algorithm applied to non-small cell lung cancer (NSCLC) was the same for all histologic subtypes… Expand
2014
2014
8008^ Background: Necitumumab (N), a human IgG1 anti-EGFR monoclonal antibody, inhibits ligand-binding and receptor activation… Expand
Review
2010
Review
2010
Necitumumab (IMC-11F8), under development by ImClone Systems in collaboration with Bristol-Myers Squibb, is a fully human IgG1… Expand
Highly Cited
2010
Highly Cited
2010
Purpose: This study aimed to determine a maximum tolerated dose (MTD) and recommended dose for disease-directed studies of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5